Quality control hardware specialist Elementar UK is urging pharmaceutical manufacturers and suppliers to bolster product testing procedures in the face of a growing threat from counterfeit drugs.
Data from the World Health Organization (WHO) suggest that up to a tenth of medical products in the developing world are counterfeit.
In Europe, Elementar said that the cost to the pharmaceutical sector could be as high as $12 billion on an annual basis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze